Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy (Q46542698)

From Wikidata

Jump to navigation Jump to search

scientific article published in July 2005

edit

Language	Label	Description	Also known as
English	Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy	scientific article published in July 2005

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

title

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

main subject

patient

0 references

breast carcinoma

1 reference

based on heuristic

inferred from title

author name string

Allan Lipton

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Kim Leitzel

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Suhail M Ali

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Laurence Demers

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Harold A Harvey

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Hilary A Chaudri-Ross

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Dean Evans

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Raquel Lang

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Wolfgang Hackl

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Peter Hamer

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

Walter Carney

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

language of work or name

English

0 references

publication date

1 July 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

published in

Cancer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

volume

104

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

page(s)

257-263

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

cites work

Oestrogen receptor: a stable phenotype in breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

21 January 2018

Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

21 January 2018

Mechanisms of tamoxifen resistance

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring therapy by serum HER-2/neu

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R ty

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FCNCR.21202

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.21202

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

PubMed publication ID

15952182

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15952182

retrieved

23 December 2017

reference URL

http://europepmc.org/abstract/MED/15952182

ResearchGate publication ID

7790849

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46542698&oldid=2117408040"